{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=16", "query": { "condition": "Neuroendocrine Carcinoma", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 946, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T13:00:30.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04261439", "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "In Escalation: All Patients With Solid Tumors and Lymphoma", "In Expansion: Melanoma, Non-small Cell Lung Cancer" ], "interventions": [ { "name": "NIZ985", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-02-27", "completion_date": "2023-12-27", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 2, "location_summary": "Duarte, California • La Jolla, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04261439" }, { "nct_id": "NCT03543969", "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Melanoma (Skin)", "Skin Cancer", "Skin Melanoma", "Skin Carcinoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-06-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543969" }, { "nct_id": "NCT05896839", "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Metastatic Basal Cell Carcinoma", "Metastatic Carcinoma in the Skin", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Unresectable Basal Cell Carcinoma", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-07-24", "completion_date": "2027-08-02", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 26, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896839" }, { "nct_id": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Soft Tissue Sarcoma (STS)", "Platinum-resistant Ovarian Cancer (PROC)", "Hepatocellular Carcinoma (HCC)", "Colorectal Cancer (CRC)", "HER2 Negative Breast Cancer", "Cutaneous Melanoma", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "GI-102 subcutaneous (SC)", "type": "DRUG" }, { "name": "GI-102", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "eribulin", "type": "DRUG" }, { "name": "trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2023-05-30", "completion_date": "2027-04-24", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05824975" }, { "nct_id": "NCT04254107", "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Carcinoma", "Gastroesophageal Junction Carcinoma", "Classical Hodgkin Lymphoma", "Diffuse Large B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Cutaneous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Triple Negative Breast Cancer", "Cervical Cancer" ], "interventions": [ { "name": "SEA-TGT", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" }, { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2020-05-29", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04254107" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT01603004", "title": "Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Neuroendocrine Cancer" ], "interventions": [ { "name": "MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-05-14", "completion_date": "2019-06-24", "has_results": false, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01603004" }, { "nct_id": "NCT01496313", "title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "300mg vandetanib", "type": "DRUG" }, { "name": "150mg vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2012-06-08", "completion_date": "2024-07-11", "has_results": true, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496313" }, { "nct_id": "NCT05155033", "title": "Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Advanced Locoregional Melanoma", "Metastatic Renal Cell Carcinoma", "Clear Cell Histology" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 78, "start_date": "2022-08-18", "completion_date": "2031-09-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05155033" }, { "nct_id": "NCT03207347", "title": "A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma", "Uveal Melanoma", "Renal Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 37, "start_date": "2018-08-13", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-14T13:00:30.817Z", "location_count": 3, "location_summary": "Gainesville, Florida • Miami, Florida • Orlando, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207347" } ] }